Effect of Shexiang Tongxin Dropping Pills on Microcirculation in Patients With AMI

• Status: Not yet recruiting
• Trial end date: 2023-07-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is a randomized, controlled clinical trial. Evaluation of microcirculation resistance by index of microcirculation resistance to explore the protective effect of Shexiang Tongxin dripping pills on microcirculation in patients with acute anterior myocardial infarction.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University Third Hospital

Criteria

Inclusion Criteria:

• Age ≥ 18 years old, no gender limit;

• Anterior wall STEMI within 12 hours of onset (diagnostic criteria: ischemic chest pain lasting ≥30min; ST-segment elevation or new left bundle branch block in two or more adjacent leads on the ECG; with or without Elevated myocardial markers), emergency PCI treatment is planned;

• Infarct-related coronary vascular anatomy is suitable for PCI treatment;

• Agree and cooperate to participate in this research, and sign an informed consent form

Exclusion Criteria:

• Past history of myocardial infarction history;

• The arteries related to infarction have received PCI in the past;

• Past CABG history;

• Killip grade of cardiac function ≥ grade III or cardiogenic shock;

• Systolic blood pressure ≤90mmHg;

• Bradycardia, heart rate <60 beats/min, or atrioventricular block of degree II or more;

• Allergic to Shexiang Tongxin Dropping Pills

• Past history of asthma or severe COPD;

• Severe liver and kidney dysfunction;

• Participate in other clinical trials within 3 months;

• Pregnancy or breastfeeding.